RE: U.S. Pharma Summit23 Apr 2026 09:33
P140 partnering discussions
As reiterated in recent announcements, P140 remains a core value driver for ImmuPharma. The Company continuesΒ to progress discussions with a number of potential partners, including under signed confidentiality agreements. The management team also attended the Bio-Europe Spring healthcare event in Lisbon this week,Β where a number of meetings were held in relation to P140. ImmuPharma remains focused on completing a valueβenhancing licensing deal in 2026.
The structure of the Lanstead subscription provides a mechanism through which the Company may potentially benefit from future share price performance, with the 8p Benchmark Price acting as the reference point for returns under the Sharing Arrangement. The Board therefore believes that continued operational progress and news flow relating to P140 and Kapiglucagon, have the potential to support value creation over the period of the agreement.
Importantly, the successful fundraising extends the Company's cash runway to at least H2 2028*. This strong financial leverage enhances our ability to negotiate a P140 licensing agreement from a position of strength, while also providing the flexibility to accelerate the Kapiglucagon program and selectively invest in earlier-stage pipeline opportunities.
Β
With the progress already underway, the Board believes 2026 will be a year of delivery, momentum, and success for ImmuPharma and its shareholders.
Β
Taken from elsewhere so DYOR snd NAI
From 2yrs ago concerning P140 (formerly Lupuzor)
Lupuzor prediction: Sales $5 billion pa, 30% royalty to Immupharma + $150 million pa licensing fee to Immupharma; gives $1.5 billion + $150 m = $1.65 billion pa revenues to Immupharma. 96%+ gross margin, say $1.25 billion pa net (after tax, etc), on PE ratio of 20 = $25 billion market capitalisation for Immupharma = Approx Immupharma share price Β£140.